Most Clicked StoriesMore >


Bayer suspends radium-223 production

SNMMI SmartBrief | Oct 17, 2014

Bayer HealthCare Pharmaceuticals has halted production of prostate cancer drug radium-223, sold as Xofigo, because of problems with manufacturing. Supplies of the drug have been limited since Oct. 7, according to the FDA. Bayer said it is communicating with the FDA and providers about the issue, but it had no estimate regarding when production will resume. OncLive (10/15)


Tc-99m prices expected to rise, Mallinckrodt warns

SNMMI SmartBrief | Oct 21, 2014

Review finds SPECT and PET useful in ischemic stroke management

SNMMI SmartBrief | Oct 16, 2014

OctreoPharm's radiotracer gains orphan drug status in U.S.

SNMMI SmartBrief | Oct 21, 2014

Study IDs sensitive brain areas where networks come together

SNMMI SmartBrief | Oct 15, 2014

Ketamine rapidly reverses symptom of bipolar disorder

SNMMI SmartBrief | Oct 21, 2014

N.H. breast-imaging device startup obtains $6.5M

SNMMI SmartBrief | Oct 17, 2014

"Updates on Ga-68: Outlook for the Future" webinar Thursday at 3 p.m. ET

SNMMI SmartBrief | Oct 20, 2014

Agents show promise in colorectal cancer detection

SNMMI SmartBrief | Oct 17, 2014

Lymphoseek gains expanded diagnostic indications

SNMMI SmartBrief | Oct 16, 2014


Find SNMMI SmartBrief Issues by Date:



SNMMI News More >


SNMMI 2015 Future Leaders Academy: Application deadline Oct. 31

SNMMI SmartBrief | Oct 22, 2014

Submit an abstract for the chance to represent ACNM/SNMMI in China

SNMMI SmartBrief | Oct 22, 2014

SNMMI members: Remember to "opt in" to receive print

SNMMI SmartBrief | Oct 21, 2014

New SNMMI member benefit: Free journal SAMs

SNMMI SmartBrief | Oct 21, 2014

"Updates on Ga-68: Outlook for the Future" webinar Thursday at 3 p.m. ET

SNMMI SmartBrief | Oct 20, 2014




Sign up for SNMMI SmartBrief



Designed specifically for nuclear medicine and molecular imaging professionals, SNMMI SmartBrief is a FREE, daily e-mail newsletter. It provides the latest news and information to save you time and keep you informed on our profession. Learn more